Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13289097 | 0.91 | GSK3B (0.59) | GSK3BCHEK1TSHRNAMPTCDK2 | |
| SCHEMBL12953928 | 0.91 | GSK3B (0.55) | GSK3BCHEK1TSHRNPC1NAMPT | |
| SCHEMBL13120525 | 0.91 | GSK3B (0.69) | GSK3BCDK2 | |
| SCHEMBL13289366 | 0.91 | GSK3B (0.55) | GSK3BCHEK1TSHRNAMPTCDK2 | |
| SCHEMBL14545841 | 0.89 | GSK3B (0.56) | GSK3BCHEK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12954475 | 0.89 | GSK3B (0.58) | GSK3BCHEK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14613276 | 0.89 | GSK3B (0.53) | GSK3BCHEK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14613311 | 0.89 | GSK3B (0.53) | GSK3BCHEK1CYP2C19TSHRNAMPT | |
| SCHEMBL13289009 | 0.89 | GSK3B (0.56) | GSK3BCHEK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13289101 | 0.88 | GSK3B (0.56) | GSK3BCHEK1TSHRNAMPTCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |